ATE378070T1 - Zusammensetzung mit fulvestrant - Google Patents
Zusammensetzung mit fulvestrantInfo
- Publication number
- ATE378070T1 ATE378070T1 AT02745579T AT02745579T ATE378070T1 AT E378070 T1 ATE378070 T1 AT E378070T1 AT 02745579 T AT02745579 T AT 02745579T AT 02745579 T AT02745579 T AT 02745579T AT E378070 T1 ATE378070 T1 AT E378070T1
- Authority
- AT
- Austria
- Prior art keywords
- fulvestrant
- composition
- oestra
- 17beta
- triene
- Prior art date
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 abstract 1
- 229940066675 ricinoleate Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116620.6A GB0116620D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378070T1 true ATE378070T1 (de) | 2007-11-15 |
Family
ID=9918096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745579T ATE378070T1 (de) | 2001-07-07 | 2002-07-03 | Zusammensetzung mit fulvestrant |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040175402A1 (de) |
| EP (1) | EP1409021B1 (de) |
| JP (1) | JP4295087B2 (de) |
| AT (1) | ATE378070T1 (de) |
| AU (1) | AU2002317298A1 (de) |
| CY (1) | CY1107142T1 (de) |
| DE (1) | DE60223542T2 (de) |
| DK (1) | DK1409021T3 (de) |
| ES (1) | ES2294146T3 (de) |
| GB (1) | GB0116620D0 (de) |
| PT (1) | PT1409021E (de) |
| WO (1) | WO2003006063A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112837A1 (ja) * | 2003-05-23 | 2004-12-29 | Hisamitsu Pharmaceutical Co., Inc. | 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン－１α生成抑制剤 |
| CN100571696C (zh) * | 2005-01-05 | 2009-12-23 | 国防教育研究基金会 | 尿苷二磷酸-葡萄糖醛酸基转化酵素2b(ugt2b)的抑制剂及促进剂 |
| JP2009509942A (ja) * | 2005-09-26 | 2009-03-12 | ホスピラ・オーストラリア・ピーティーワイ・リミテッド | フルベストラント製剤 |
| CA2619476A1 (en) * | 2005-10-05 | 2007-04-19 | Sicor Inc. | Separation of fulvestrant isomers |
| US9180088B2 (en) | 2008-03-07 | 2015-11-10 | Scidose, Llc | Fulvestrant formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| BR112013029758A2 (pt) | 2011-05-20 | 2018-10-09 | Capital, Business Y Gestion De Finanzas S.L. | composição farmacêutica |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| WO2015157752A1 (en) * | 2014-04-11 | 2015-10-15 | Sam Houston State University | Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote |
| EP3675863A4 (de) | 2017-09-01 | 2021-01-27 | PTC Therapeutics MP, Inc. | Pharmazeutische zusammensetzungen mit sepiapterin und verwendungen davon |
| CN108159055A (zh) * | 2018-01-04 | 2018-06-15 | 西安力邦医药科技有限责任公司 | 治疗乳腺癌的长效递药系统、其制备方法及应用 |
| EP3747442B1 (de) * | 2018-01-31 | 2024-07-10 | FUJIFILM Corporation | Verfahren zur herstellung eines injektionspräparats |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| CN116600828A (zh) * | 2020-12-04 | 2023-08-15 | 三养控股公司 | 氟维司群的缓释药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2001
- 2001-07-07 GB GBGB0116620.6A patent/GB0116620D0/en not_active Ceased
-
2002
- 2002-07-03 DK DK02745579T patent/DK1409021T3/da active
- 2002-07-03 AU AU2002317298A patent/AU2002317298A1/en not_active Abandoned
- 2002-07-03 DE DE60223542T patent/DE60223542T2/de not_active Expired - Lifetime
- 2002-07-03 AT AT02745579T patent/ATE378070T1/de active
- 2002-07-03 US US10/482,739 patent/US20040175402A1/en not_active Abandoned
- 2002-07-03 ES ES02745579T patent/ES2294146T3/es not_active Expired - Lifetime
- 2002-07-03 WO PCT/GB2002/003084 patent/WO2003006063A2/en not_active Ceased
- 2002-07-03 EP EP02745579A patent/EP1409021B1/de not_active Expired - Lifetime
- 2002-07-03 JP JP2003511868A patent/JP4295087B2/ja not_active Expired - Fee Related
- 2002-07-03 PT PT02745579T patent/PT1409021E/pt unknown
-
2008
- 2008-01-15 CY CY20081100057T patent/CY1107142T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002317298A1 (en) | 2003-01-29 |
| US20040175402A1 (en) | 2004-09-09 |
| PT1409021E (pt) | 2008-01-11 |
| JP2004521151A (ja) | 2004-07-15 |
| CY1107142T1 (el) | 2012-10-24 |
| WO2003006063A2 (en) | 2003-01-23 |
| WO2003006063A3 (en) | 2003-05-15 |
| JP4295087B2 (ja) | 2009-07-15 |
| EP1409021A2 (de) | 2004-04-21 |
| DE60223542T2 (de) | 2008-11-13 |
| EP1409021B1 (de) | 2007-11-14 |
| DE60223542D1 (de) | 2007-12-27 |
| ES2294146T3 (es) | 2008-04-01 |
| DK1409021T3 (da) | 2008-02-11 |
| GB0116620D0 (en) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107142T1 (el) | Τυποποιηση που περιλαμβανει fulvestrant | |
| BG106833A (en) | Fulvestrant formulation | |
| BR9909329A (pt) | Método para estabilizar composições farmacêuticas pelo uso especial de um antioxidante | |
| IL188774A0 (en) | Compositions for delivery of drug combinations | |
| NO20034149D0 (no) | Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel | |
| BR0307893A (pt) | Formulação oftálmica com sistema de goma | |
| ZA200709188B (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| PT1299348E (pt) | Compostos e composições para administração de agentes activos | |
| MXPA05008913A (es) | Formulacion oftalmica estable que contiene antibiotico y corticoesteroide. | |
| MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
| BR0212386A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BR0308486A (pt) | Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger | |
| WO2004004639A3 (en) | A novel stable formulation | |
| MXPA04000028A (es) | Formulacion farmaceutica para la administracion intramuscular de fulvestrant. | |
| DE60133198D1 (en) | Glykopeptidderivate mit carboxysacchariden | |
| GT200100063A (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos | |
| MXPA05010613A (es) | Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo. | |
| NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
| YU6102A (sh) | Farmaceutski preparat i njegova primena | |
| AU2369801A (en) | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation | |
| BR0010499A (pt) | Agentes endoparasiticidas | |
| WO2004078677A3 (en) | Enhanced delivery of sphingolipids | |
| AU2624499A (en) | Oral compositions at low dosage of cytotoxic proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1409021 Country of ref document: EP |